eSight 4 Medical Device for the Visually Impaired Now Available in the United Kingdom, Germany and France

October 28, 2020

eSight4 is now available in select European countries, expanding its goal of providing sight to people with visual impairment on a global basis. The news was announced today. The wearable medical device can be purchased in the United Kingdom, Germany and France, with more countries to be added in 2021.

eSight 4 obtained its CE Mark in August, meeting the European Union’s standards for health, safety and environmental protections.

“Since the launch of eSight 4 in North America, response from vision care specialists, distributors of assistive technology and the low vision community has exceeded our expectations. We’ve heard from people in Europe who can’t wait to get their hands on the device. Our expansion into Europe is the first step in reaching a larger audience, so we can change lives for even more people around the world,” said Gregory Ogorek, eSight’s Chief Operating Officer and President, International.

According to the European Blind Union, there’s an estimated 30 million blind or partially sighted people in Europe, and an average of one in 30 Europeans experience some form of significant sight loss. Of this group, the average unemployment rate is over 75%, but with eSight this number could be significantly reduced as it allows people living with visual impairments to perform job duties.

eSight 4 device works by combining a best-match camera and lens technology with advanced sensors and proprietary algorithms to maximize the quality of information sent to the brain, which in turn dramatically augments sight. A typical eSight user has visual acuities from 20/60 to 20/800, with some as high as 20/1400, caused by more than 20 different eye conditions including macular degeneration, diabetic retinopathy and Stargardt’s disease. Wearing eSight, many achieve 20/20 acuity.

Wireless and hands-free, with vision controls built right into the headset, eSight 4 is the most mobile device yet, allowing users to remain active, while enjoying the benefits of eSight. New features include:

  • A halo band to improve comfort with an easy-to-swap battery in the back that evenly distributes the weight around the head for all-day use.
  • eSight’s patented bioptic tilt, which allows users to see what’s in front of them and what’s around them with their natural peripheral vision.
  • The new device is cloud-based, so wearers are provided with easy and instant access to the latest features and can invite loved ones to see what they are seeing and help manage their eSight experience.
  • Mobile apps for Android® and Apple® smartphones provide advanced features including the ability to view their mobile screen on their eSight where they can freeze and zoom to see tiny details, stream videos on their phone and view it through their eSight, as well as save and share photos and videos captured on their eSight.

“Just looking at the statistics from the European Blind Union, it’s clear there’s a need for eSight in the continent,” said Ogorek. “Our expansion into Europe is the tip of the iceberg, but will benefit thousands of more individuals so they can return to work and enjoy all aspects of daily life.”

Distributors of assistive technology and eye care professionals interested in representing eSight 4, as well as individuals interested in more information on how eSight can benefit you or someone you know, visit here.

SourceeSight 4

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version